Darzalex (Daratumumab approved)

Darzalex (Daratumumab approved)

Today it was announced that Danish biotech company Genmab has its 2nd cancer drug approved. The U.S. FDA has approved DARZALEX™ injection for intravenous infusion for the treatment of patients with multiple myeloma. Genmab almost doubled their estimate for 2015 with a milestones from Janssen of 45 USD Million. We are so happy on behalf of the company, their shareholders …

Read more.

Genmab - what happens next?

Genmab is trading 11% higher today on the approval of Daratumumab. The approval came very fast - underlining the fact that the FDA and medical community have been very eager to get this treatment to patients - fast. Several analysts have adjusted their 12-month target to the 949-1000 range, but this is merely to reflect that they still recommend investors to …

Read more.

---

Poised to pop - follow up

3 months ago we selected 3 stocks that could go 30% higher. The stocks in question was Biotek Pharmacon, Alstom and Celladon.You can read the article here http://inrater.com/3-stocks-poised-to-pop-30-in-3-months/ Our timing was good for Alstom and Celladon and exceptionally great with Biotek Pharmacon, which popped almost 100% from 9 to 18 NOK. We sold our position before, banking a 30% return on …

Read more.

The gateway to small- and midcap stocks in Scandinavia. Steen has more than 15 years hands-on expericence in analysing and investing in stocks. He is a weekly contributor and analyst in “Aktieugebrevet”, one of the leading sources of independent analysis in Denmark.

Peter Hildebrandt, also known as “Akademikeren”, has been investing for more than 17 years. Mainly invests in Undervalued technology and biotech stocks and is currently rotating towards dividend stocks in energy and shipping.

I’m a ten year veteran of biotechnology, and currently pursuing my MBA from UCLA.  I use my knowledge of the industry and business to make my investing decisions.  I look for small to mid-cap biotech companies with innovative research and buy into their company during clinical trials.

Andreas is providing stock tips with deep fundamental research behind each stock he recommends. He is privately a portfolio manager at his own Investment company where he Invest in stocks, options, CFD’s etc. with a balanced long/short approach.

Jacob’s approach is to search for that which is undervalued and where the discount to the intrinsic value provides a large margin of safety. He believes sectors that are either out of favor or in distress typically offer the best opportunities.